Amylyx Pharmaceuticals Inc Financial Flexibility Index
Amylyx Pharmaceuticals Inc financial flexibility index. Amylyx Pharmaceuticals Inc (AMLX) has a Financial Flexibility Index of -1.24x as of June 2026. Free cash flow of $-31.39 Million (operating CF $-31.42 Million minus capex $30.00K) represents -1% of total liabilities ($25.40 Million). See Amylyx Pharmaceuticals Inc free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Amylyx Pharmaceuticals Inc (2019–2025)
Financial flexibility index of Amylyx Pharmaceuticals Inc from 2019 to 2025. Historical Financial Flexibility Index trend for Amylyx Pharmaceuticals Inc across 7 annual periods. Check AMLX cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Amylyx Pharmaceuticals Inc Financial Flexibility Index by Year (2019–2025)
Amylyx Pharmaceuticals Inc financial flexibility index by year from 2019 to 2025. Year-by-year free cash flow to debt coverage for Amylyx Pharmaceuticals Inc. For the full cash flow conversion analysis, see AMLX cash flow metrics.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -4.50x | $-123.20 Million | $-123.34 Million | $27.39 Million | ▲ +22.5% |
| 2024 | -5.80x | $-167.49 Million | $-167.65 Million | $28.87 Million | ▼ -3804.2% |
| 2023 | 0.16x | $13.16 Million | $11.92 Million | $84.02 Million | ▲ +104.5% |
| 2022 | -3.49x | $-177.34 Million | $-179.87 Million | $50.85 Million | ▼ -1103.1% |
| 2021 | -0.29x | $-74.45 Million | $-74.80 Million | $256.78 Million | ▲ +35.9% |
| 2020 | -0.45x | $-36.55 Million | $-36.70 Million | $80.83 Million | ▼ -22.6% |
| 2019 | -0.37x | $-10.54 Million | $-10.69 Million | $28.58 Million | — |